Saxenda
Also called liraglutide weight loss, liraglutide 3 mg.
By Dr Chad Okay3 min read
Saxenda is the brand name Novo Nordisk uses for liraglutide injections at a 3 mg daily dose, licensed for weight loss. It was the first GLP-1 receptor agonist approved for weight management. Most prescribers have shifted to weekly options like Wegovy and Mounjaro because daily injections are inconvenient and Saxenda produces less weight loss in trials.
What Saxenda is
Saxenda is liraglutide, a GLP-1 receptor agonist taken as a daily injection. The same molecule is sold as Victoza at 1.8 mg daily for type 2 diabetes. Saxenda goes up to 3 mg daily and is licensed for weight management in adults with a body mass index (BMI) of at least 30, or 27 with a weight-related health condition.
How it compares to Wegovy and Mounjaro
- Average weight loss: about 8% on Saxenda 3 mg at 56 weeks, against about 15% on Wegovy at 68 weeks and about 21% on tirzepatide at 72 weeks.
- Schedule: daily injection on Saxenda, weekly on Wegovy and Mounjaro.
- Side effects are similar (nausea, constipation, reflux) but daily peaks make Saxenda nausea more variable across the day.
- Cost: usually similar per month, but Saxenda needs many more pens because of the daily schedule.
Why it's still prescribed
Saxenda was the first GLP-1 receptor agonist approved for weight management (FDA, December 2014), so it has the longest post-launch track record of the weight-loss GLP-1 drugs. It is sometimes preferred when a clinician wants the option to escalate or back down quickly (because the half-life is shorter than weekly drugs) or when supply of weekly options has been disrupted. Some people also tolerate the daily ramp better than the weekly peak and trough.
Side effects
- Nausea: very common in the first 4 to 8 weeks.
- Constipation: common, gut transit slows.
- Diarrhoea: common in a smaller subset.
- Reflux and burping.
- Injection-site reactions are common because of daily injecting.
- Rare but serious: pancreatitis, gallstones, delayed gastric emptying. Severe, persistent abdominal pain needs a doctor the same day, not a wait-and-see approach (see below).
If something feels wrong
This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.
Common questions
Wegovy produces more weight loss on average and is a weekly injection rather than daily. Most prescribers default to Wegovy unless there's a specific reason to choose Saxenda (supply, taper flexibility, individual tolerance).
Sources
- 1Saxenda (liraglutide) EMA summary of product characteristics: indication, 3.0 mg dosing, 13-hour half-life, adverse reactionsEuropean Medicines Agency
- 2Saxenda 6 mg/mL solution for injection (liraglutide) SmPC: adverse reactions and delayed gastric emptyingEMC (UK)
- 3NICE TA664: liraglutide for managing overweight and obesity (recommendation 1.1, BMI ≥ 35, non-diabetic hyperglycaemia, specialist tier 3 service)NICE
- 4Pi-Sunyer et al 2015, SCALE Obesity and Prediabetes: liraglutide 3.0 mg, 8.0% vs 2.6% weight loss at 56 weeks (population pharmacokinetic analysis reporting the SCALE result)Clinical Pharmacokinetics (PMC)
- 5Wilding et al 2021, STEP 1: once-weekly semaglutide 2.4 mg, -14.9% body weight at week 68New England Journal of Medicine (PubMed)
- 6Jastreboff et al 2022, SURMOUNT-1: tirzepatide once weekly, -20.9% at 15 mg at week 72New England Journal of Medicine (PubMed)
- 7Drugs@FDA: Saxenda (liraglutide) NDA 206321 - original approval for chronic weight management December 2014; adolescent 12-17 indication added December 2020US Food and Drug Administration
- 8Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
Related terms




